David Janowsky: Cholinergic muscarinic mechanisms in depression and mania
Samuel Gershon’s further comment
I read this vast assembly of material (Janowsky 2019) and find it to be encyclopedic and educational. However, we still have some of the basic questions unanswered. Yes, bio-transmitters in the brain (which ones?) actually are responsible for what? I ended my 2019 note on the discussion with Dave Janowsky asking this question after the presentation of the papers in that series.
However, now I have a real discovery for all you readers to admire and scratch your heads – Brexpiprazole. This compound is approved in various countries for the treatment of schizophrenia and MDD.
Pay Attention: "…brexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5 HT1A and Dopamine D2 receptors and an antagonist at 5 HT 2A and noradrenaline alpha 1b2C receptors all with sub-nanomolar affinity” (McEvoy and Citrome 2016).
Now, this is a brain twister; and people say we are not making any progress in psychopharmacology.
Gershon S. Samuel Gershon’s opening comments. Cholinergic muscarinic mechanisms in depression and mania. inhn.org.controversies. October 10, 2019.
Janowsky D. David Janowsky: Cholinergic muscarinic mechanisms in depression and mania. inhn.org.controversies. September 12, 2019.
McEvoy J, Citrome L. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. Clin Schizophr Relat Psychoses, 2016;9(4):177-86.
May 13, 2021